Marie-Paule Kieny
Director of Research at INSERM

…the research publications of the Gamaleya Institute support the data of the Russian Direct Investment Fund (RDIF) on the efficacy of Sputnik V against the coronavirus infection.

Hugo Pizzi
Infectious Disease Specialist, Epidemiologist, Master in Public Health, and Professor at the National University of Córdoba

So, having 2 different types of viral vectors allows of immunizing people more strongly. Now, the world started working to see if one could combine the second dose of one brand with the first one of another brand but, in general, I am convinced that we should respect the creators.

Gaeqa Saeed Al-Saleh
Bahrain's Health Minister

Our data has confirmed the high efficacy and safety of Sputnik V during its use in Bahrain. This vaccine is one of a number of approved vaccines made available free of charge to citizens and residents in the Kingdom.

Mohammed Ahmed Al-Jaber
UAE Ambassador to Russia

The final phase of research and clinical trials showed that the Sputnik V vaccine’s effectiveness stands at 91.4%, while the vaccine prevents 100% of severe cases. From the first days of the pandemic, Russia and the UAE have emphasized the importance of joint efforts to prevent the coronavirus from spreading.

Gulyás Gergely
Member of the National Assembly of Hungary

The results of all the tests will be announced. However, according to the data available today, the vaccination results (in case of some vaccines — in the amount of over half a million doses, and in case of others — in the amount of one million doses) show that the Sinopharm vaccine is better than Pfizer, but Sputnik is the best of all.

Peter Altmaier
Minister of Economics

Both Germany and Russia, with Biontech and Sputnik V, are among the pioneers in the development of vaccines against corona. Naturally, Sputnik V must be approved in the European Union.

Alberto Fernández
President of Argentina

We are very excited about the possibility of producing Sputnik V in Argentina, a vaccine with which we are already protecting a large part of our population with excellent results. It will be a great opportunity to advance in the fight against the pandemic not only in Argentina, but also in Latin America.

Dr Naor Bar-Zeev
International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, USA

Dr. Tom Inglesby
Director of the Center for Health Security of the Johns Hopkins Bloomberg School of Public Health

The two studies by Logunov and colleagues have several strengths. First, adenoviruses are ubiquitous, so humans might not be immunologically naive. A second strength is the threshold for neutralisation used in the two studies. A third strength is that the vaccine, similar to other before it, induced broad immune responses. Although not specifically discussed, the results imply a T-helper1-cell-weighted response that might be important for vaccine safety, potentially reducing the risk of antibodydependent enhanced disease. A fourth strength was development of two vaccine formulations, frozen and lyophilised. A lyophilised formulation could mean stability within the existing global vaccine refrigerated cold chain that is needed to maintain vaccine efficacy from factory to recipient, a hurdle other vaccines are yet to address. Although more costly to produce at scale, product stability will maximise reach in remote terrain, a must if universal and equitable coverage is to be achieved.

Prof Nadey Hakim
Vice President of the British Red Cross, Vice President of the International Medical Sciences Academy

The results of clinical trials of the Russian vaccine Sputnik V have demonstrated impressive results, which have now been recognized by the international medical community. The vaccine has been shown to be safe and effective with no serious side effects identified and uses a proven platform based on human adenoviral vectors, which is currently the safest mechanism for introducing the genetic code of the virus spike into the human body. This approach has been thoroughly studied not only in Russia but also internationally. Russia has a long and successful track record developing vaccines and remains a global leader in this field. We hope that the vaccine will soon become available across the world to help stop the devastating pandemic and enable people to return to normal life.

Dr Muhammad Munir
Lecturer in Molecular Virology at the Lancaster University

There are features that make Sputnik V a promising candidate. The idea of using two different adenoviruses as vector is superior over many vaccines in the frontline. Generally, the immune system perceive the vector proteins as antigen similar to the S protein of SARS-CoV-2, so it elicit immune response against those proteins as well. If people are reimmunized (as second dose or repeated vaccine), the pre-existing immunity can compromise the efficacy of second vaccine dose. Using a vector of different nature, as is the in Sputnik V, will avoid this problem.

Message has been successfully sent!

Thank you!
You have been subscribed